Research
Size:
Share:

RUBY – Sponsored by Regeneron Pharmaceuticals, Inc.

Completed Study | Duration: 36 weeks

RUBY REGN910-3 was a multi-center, prospective, and randomized Phase II clinical trial for the treatment of Diabetic Macular Edema (DME). It compared the efficacy of intravitreal REGN910-3 at different doses vs. intravitreal Eylea® (aflibercept). REGN910-3 is a new anti- angiopoietin-2 antibody that is a co-formulation of REGN910 and aflibercept. Like VEGF, Angiopoietin-2 is a key growth factor in the formation of new blood vessels. This trial was for patients 18 years of age and older with Diabetic Macular Edema due to Diabetic Retinopathy and no history of treatment within the last three months. Participants were treated and followed for 36 weeks.

Return to Diabetic Retinopathy